Evidence map›Paper›PMID 40387836›Full record

ArticleOncotarget2025

Immune-mediated adverse events following atezolizumab and bevacizumab in a multinational Latin American cohort of unresectable hepatocellular carcinoma.

Leonardo Gomes da Fonseca, Federico Piñero, Margarita Anders, Carla Bermudez, Ezequiel Demirdjian, Adriana Varón, Daniela Perez, Jorge Rodriguez, Oscar Beltrán, Ezequiel Ridruejo and 10 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Leonardo Gomes da Fonseca *Instituto do Cancer do Estado de São Paulo, Hospital das Clínicas, Universidade São Paulo, Brazil.
Federico Piñero *Hepatology and Liver Transplant Unit, Hospital Universitario Austral, Argentina.
Margarita AndersDepartment of Hepatology, Hospital Alemán, Argentina.
Carla BermudezDepartment of Hepatology and Liver Transplantation, Hospital Italiano de Buenos Aires, Argentina.
Ezequiel DemirdjianDepartment of Liver Transplantation, Sanatorio Sagrado Corazón, Argentina.
Adriana VarónDepartment of Hepatology, Fundación Cardioinfantil, Colombia.
Daniela PerezDepartment of Gastroenterology, Hospital Padilla, Tucumán, Argentina.
Jorge RodriguezDepartment of Liver Transplantation, Hospital Central de Mendoza, Argentina.
Oscar BeltránDepartment of Hepatology, Fundación Cardioinfantil, Colombia.
Ezequiel RidruejoDepartment of Hepatology, Centro de Educación Médica e Investigaciones Clínicas (CEMIC), Argentina.
Pablo CaballiniDepartment of Gastroenterology, Hospital Centenario de Rosario, Santa Fe, Argentina.
Alexandre AraujoDepartment of Gastroenterology, Hospital das Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Brazil.
Juan Diego Torres FlorezDepartment of Gastroenterology, Hospital Universitario Fundación Santa Fe de Bogotá, Colombia.
Juan Ignacio MarínDepartment of Hepatology and Liver Transplantation, Hospital Pablo Tobón Uribe, Medellín, Colombia.
Marina VillaDepartment of Internal Medicine, Hospital Comarcal de Blanes, Córdoba, Argentina.
Federico OrozcoDepartment of Hepatology, Hospital Alemán, Argentina.
Jaime PoniachikDepartment of Gastroenterology, Hospital Clínico de la Universidad de Chile, Chile.
Sebastián MarcianoDepartment of Hepatology and Liver Transplantation, Hospital Italiano de Buenos Aires, Argentina.
Fernando BessoneDepartment of Gastroenterology, Hospital Centenario de Rosario, Santa Fe, Argentina.
Manuel MendizabalHepatology and Liver Transplant Unit, Hospital Universitario Austral, Argentina.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsLatin America has been underrepresented in trials evaluating immunotherapy for hepatocellular carcinoma (HCC). We aimed to describe the incidence of immune-related adverse events (irAEs) and their impact on outcomes in a Latin American cohort.

methodsA multicenter prospective study was conducted in Argentina, Brazil, Chile, and Colombia, including patients who received atezolizumab plus bevacizumab. A time-covarite proportional hazard analysis evaluated the effect of irAEs.

results99 patients were included. The median treatment duration was 6 months, with a median survival of 17.0 months (95% CI: 12.6-19.8). The irAE incidence rate was 2.1 cases per 100 persons-months (cumulative incidence 18.1% (95% CI: 11.1-27.2%)). Median time to irAE was 2.3 months (range 1.4-4.8), most frequently hepatitis (

conclusionThe incidence of irAEs in this cohort is lower than reported in controlled trials, withouut impact on survival outcomes. Education and early recognition are crucial to ensure that these events are identified and addressed.

Indexed as

Antibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBevacizumabCarcinoma, HepatocellularLiver NeoplasmsAdultAgedAged, 80 and overFemaleHumansIncidenceLatin AmericaMaleMiddle AgedProspective StudiesTreatment OutcomeAntibodies, Monoclonal, HumanizedatezolizumabBevacizumabadverse eventsimmunologyimmunotherapyliver cancerreal-world

Identifiers

PMID40387836
PMCPMC12088043

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.